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See Article, pages 656–662No discussion of cancer biology is complete without mention of
tumor suppressor p53 and its stress-activated protection of the
genome. A plethora of regulatory signaling impinges on p53 to
either limit p53 protein levels, in the absence of stress signaling,
or to rapidly induce protein levels and mediate cell cycle arrest or
cell death in the face of threats to genome integrity [1,2].
Although reports of p53 regulation and functions in cellular sur-
veillance add up to an astounding number, recent discoveries
that illustrate functions of p53 in cellular metabolism reveal that
much is left to learn [3,4]. The ability of the p53-null mouse to
survive to adulthood with few apparent challenges to normal
development casts a shadow over likely roles for p53 in normal,
cellular homeostasis [5]. Early development of speciﬁc tumors,
the proﬁle of which is dependent on strain, is the most striking
phenotype of p53/ mice. However, closer examination of these
mice reveals that all is not perfect during development, as female
mice lacking p53 have diminished fecundity and a signiﬁcant
number exhibits exencephaly [6]. Additionally, once other struc-
turally similar members of the p53 family were uncovered,
including p63, p73 and multiple isoforms of all p53 family mem-
bers, complexity in their potential cross-talk or functional com-
pensation was suspected. This was borne out by the altered
proﬁles of tumors that develop in mice variously depleted in
the family members; for example, p53+/; p73+/ mice develop
hepatocellular carcinoma (HCC) and other tumors never found
in p53+/ or p53/ mice [7]. Clearly, levels of p53 are carefully
regulated during embryogenesis, as deletion of the primary
negative regulator of p53 protein levels, Mdm2, leads to early
embryonic lethality at implantation [8,9].
In this issue of the Journal of Hepatology, Rotter and colleagues
broaden the scope of p53 regulatory functions in normal cellular
homeostasis by uncovering p53-mediated transcription of spe-
ciﬁc genes that function in lipid metabolic pathways (Goldstein
et al., this issue). The use of hepatic tissue and cells to uncoverJournal of Hepatology 20
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priate, as the liver is a key player in lipid intake, synthesis, pro-
cessing and secretion [10]. At ﬁrst glance, the liver would not
seem a likely site where p53 would have a major functional role.
Unlike many other tissues, the liver is non-responsive to whole-
body irradiation, showing no p53 activation or induction of pro-
tective apoptotic pathways [11]. Speciﬁc mutations in the gene
encoding p53 occur in HCC, but often arise relatively late during
tumorigenesis or are secondarily induced as a result of environ-
mental insults, such as adducts formed in the presence of aﬂa-
toxin poisoning [12,13]. However, dysfunction in p53, due to
inactivation by proteins produced in hepatitis B or C infection,
is likely causal in virus-associated HCC [14]. More recent studies
of genome wide expression patterns in human and mouse HCC
suggest a signature of pathways associated with tumor develop-
ment, among which p53 regulation and intersection are signiﬁ-
cant [15].
Goldstein et al. use a variety of platforms to assess hepatic
functions for p53, not only in human hepatic tumor-derived, cul-
tured cell lines but also in donor liver primary hepatocytes,
mouse hepatocytes and embryonic ﬁbroblasts. In an unbiased
approach, microarray analysis of gene expression was carried
out in human hepatoblastoma-derived HepG2 cells, engineered
by retroviral introduction of shRNA targeting p53 or control
shRNA, and further altered in p53 expression levels by exposure
to the inhibitor Nutlin. The speciﬁc mechanism of Nutlin-medi-
ated stability of p53, due to disruption of Mdm2-p53 interaction
without exposure to DNA damaging agents or induction of geno-
toxic stress [16], may have been critical in linking p53 to hepatic
genes active in lipid metabolism; robust activation of early
response genes, active in damage control or cell death, could
potentially obscure expression of other p53-regulated genes.
Over 300 genes were signiﬁcantly activated in this study, of
which 5% were associated with lipid metabolism.
The group of genes, classiﬁed as lipid metabolic pathway
genes, covers multiple aspects of lipid metabolism, including reg-
ulators of intracellular ceramide and fatty acids, systemic lipid
absorption and lipoprotein metabolism. The authors performed
detailed, in-depth analyses to show that p53 directly regulates
speciﬁc genes from the larger number in this category:12 vol. 56 j 518–519
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(1) phospholipid transfer protein (PLTP), which is secreted by the
liver as an HDL-bound protein and is associated with
atherogenesis [17,18]. (2) Carboxyl ester lipase (CEL), an enzyme
that hydrolyzes dietary triglycerides and ceramide, and promotes
uptake of HDL-associated cholesteryl esters in the liver [19].
(3) Adenosine triphosphate-binding cassette, subfamily A, mem-
ber 12 (ABCA12), a member of the large ABC superfamily of ATP-
dependent trans-membrane proteins, which functions in active
transport of lipids across the cell membrane [20]. p53-mediated
regulation of apolipoprotein levels in non-hepatic, cultured cells
was previously reported in DNA damage-induced transcription
of ApoB, which encodes the primary apolipoprotein responsible
for cholesterol transport to tissues, and Apobec1, a cytidine deam-
inase that edits Apob and Nf1 mRNA [21].
Previous linksbetweenp53, oxidative stress andmetabolic regu-
lation, as reviewed in depth byVousden and colleagues [3,4], broad-
ened the functions of p53 in tumor suppression. The metabolic
demands of tumor growth and malignant progression may induce
a switch to glycolysis, which p53 opposes by repressing glycolytic
gene expression, activating TIGAR to slow glycolysis and preventing
reactive oxidant accumulation [22]. Importantly, as shown in the
current study of lipid metabolism genes, many of these functions
of p53 in metabolic control occur during normal cellular growth
and homeostasis, as well as in response to stress induction.
With this report of p53-mediated control of speciﬁc genes in
lipid metabolism, functions of p53 are further extended from
tumor suppression to lipid-transfer control, cardiometabolic dis-
eases and atherogenesis [23]. Taken together with indirect regula-
tion of inﬂammation, by virtue of p53-mediated suppression of
NF-jB activation [24], these p53-regulated pathways may add to
the complex picture of p53 functions in aging [25]. Premature
signs of aging are also reported for TA-p63 deleted mice [26],
emphasizing that, while downstream targets of p53 are numerous,
upstream regulation of p53 is complex, inﬂuenced by a large vari-
ety of homeostatic and stress-induced controls, and likely involves
interactions among its family members and isoforms. These vari-
ables must be considered and further deﬁned to fully assess or
interpret the impact of p53 dysfunction, and to develop effective
treatments of cancers, cardiometabolic diseases and likely others,
yet to be discovered under the regulatory inﬂuence of p53.Conﬂict of interest
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